Citigroup maintains Sana Biotechnology at Buy, lowers price target to $11 from $12
Citigroup has reiterated its "Buy" rating for Sana Biotechnology but reduced its price target from $12 to $11, an 8.3% decrease. This new price target suggests a significant upside of 444.6% from the stock's closing price of $2.02 on November 13. Investors can find more detailed analyst ratings and price target data for Sana Biotechnology on the Forecasts tab and track recommendations in the News Flow section.
Morgan Stanley maintains Sana Biotechnology at Overweight, raises price target to $13 from $12
Morgan Stanley has reiterated its "Overweight" rating for Sana Biotechnology, increasing its price target to $13 from $12. This new target suggests a significant upside of 543.6% from the stock's closing price of $2.02 on November 13. Investors can find more detailed analyst data and historical recommendations for Sana Biotechnology on TradingView.
Wedbush cuts Sana Biotechnology stock price target on model changes By Investing.com
Wedbush has reduced its price target for Sana Biotechnology (NASDAQ:SANA) from $22 to $10, while maintaining an Outperform rating. This adjustment stems from changes in its valuation model, which now excludes hidradenitis suppurativa and incorporates updated financing assumptions. Despite a 42% decline in shares over the past year, the new target still implies over 300% upside from the current price, based on a sum-of-parts valuation of the company's clinical programs.
Sana Biotechnology Reports Third Quarter 2026 Financial Results and Business Updates
Sana Biotechnology reported a net income of $20.4 million, or $0.07 per share, for the third quarter of 2026, a significant improvement from a net loss in the prior year, primarily due to non-cash liability valuation gains. The company is advancing its clinical programs, with plans to initiate Phase 1/2 trials for SC451 in diabetes and SG293 in lymphoma in late 2026 and early 2027, respectively, and expects its cash runway to extend into mid-2027. A single-patient UP421 study also demonstrated promising long-term survival and function of insulin-producing cells without immunosuppression.
Sana Biotechnology Reports Third Quarter 2026 Financial Results and Business Updates
Sana Biotechnology reported its third-quarter 2026 financial results, highlighting significant progress in its clinical programs for type 1 diabetes and non-Hodgkin lymphoma. The company is advancing SC451 and SG293 towards clinical trials, with expectations of sharing data in 2027. Financially, Sana had a cash position of $121.7 million, with an expected cash runway into mid-2027.
Sana Biotechnology Q3 Results: Adjusted loss narrows to $0.14 per share
Sana Biotechnology reported a Q3 adjusted loss per share of $0.14, outperforming analyst estimates of $0.15 by 6.67%. This narrower loss indicates improved operational efficiency compared to the previous year. The company's stock has seen significant declines over various periods, including a 40.27% drop over the last year and an 89.28% decrease over five years.
Sana: Q3 Earnings Snapshot
Sana Biotechnology Inc. (SANA) reported third-quarter earnings of $20.4 million, translating to a net income of 7 cents per share. Despite losses adjusted for non-recurring gains at 14 cents per share, the results surpassed Wall Street's expectations, which had estimated a loss of 18 cents per share. This financial performance was generated by Automated Insights using data from Zacks Investment Research.
Sana Biotechnology, Inc. (SANA) Tops Q3 EPS by 1c
Sana Biotechnology, Inc. (NASDAQ: SANA) announced its Q3 earnings, reporting an EPS of ($0.14). This figure was $0.01 better than the analyst estimate of ($0.15), indicating a positive surprise for investors. The article also provides a quick overview of SANA's stock price and recent performance.
A Fidelity pool holds 5.1% of Sana Biotechnology (SANA). FMR’s reported stake is larger.
FMR LLC and Abigail P. Johnson reported beneficial ownership of 37,293,854 common shares, representing 12.5% of Sana Biotechnology (SANA) as of September 30, 2026. This disclosure was made in a Schedule 13G/A filing. Separately, a Fidelity Growth Company Commingled Pool's interest in SANA was noted at 15,131,616 shares, or 5.1% of the outstanding common stock, as of the same date.
Sana Biotechnology Reports Third Quarter 2026 Financial Results and Business Updates
Sana Biotechnology reported its third-quarter 2026 financial results, highlighting significant progress in its clinical programs. The company is advancing towards initiating Phase 1/2 trials for SC451 in type 1 diabetes and a clinical study for SG293 in non-Hodgkin lymphoma, with data expected in 2027. Sana also announced a follow-on publication in The New England Journal of Medicine detailing long-term data for UP421 in type 1 diabetes without immunosuppression, and reported a cash position of $121.7 million, providing a runway into mid-2027.
Sana Biotechnology, Inc. (SANA) Seasonal Returns Chart - Yahoo Finance
The article provides a seasonal returns chart for Sana Biotechnology, Inc. (SANA), displaying average monthly price returns from 2021 to 2026. It includes current stock information, showing SANA at $2.57, down 5.51% at close on October 30, with no change in after-hours trading. The page focuses on historical seasonality data for the stock.
SANA Q3'26 Earnings: revenue estimate is 0 USD
Sana Biotechnology, Inc. (SANA) is scheduled to release its Q3'26 earnings on November 05. The company's revenue estimate for the quarter is 0 USD, with an anticipated EPS of (0.15) USD. Historical EPS data and estimates for previous quarters are also provided.
Sana Biotechnology, Inc. Estimates – NASDAQ:SANA
This article provides an overview of Sana Biotechnology, Inc. (NASDAQ: SANA) financial data and analyst estimates available on TradingView. It directs users to explore reported financial data, compare actual results with estimates across various financial statements, and visualize trends over time for informed investment decisions. The content explicitly states that it is not investment advice and advises users to conduct their own research.
Form 4 Sana Biotechnology Inc For: 11 October By Investing.com
This article announces the filing of Form 4 for Sana Biotechnology Inc. on October 11th. It provides basic stock market data for SANA and other indices, commodities, and bonds, indicating general market performance at the time of publication. The content primarily serves as a placeholder for the Form 4 filing information, with additional market data.
Form 4 Sana Biotechnology Inc For: 11 October By Investing.com
This article from Investing.com reports on a Form 4 filing for Sana Biotechnology Inc. on October 11. It's a brief announcement providing specific financial regulatory information. The core content is the Form 4 details, with additional stock market data and related news.
Form 4 Sana Biotechnology Inc For: 11 October By Investing.com
This article from Investing.com reports on a Form 4 filing for Sana Biotechnology Inc. dated October 11. It's a very brief notice, providing no further details about the content of the Form 4. The article also lists current market data for various indices, commodities, and shares.
Form 4 Sana Biotechnology Inc For: 11 October By Investing.com
This article announces the filing of Form 4 by Sana Biotechnology Inc. on October 11. It provides no further details about the content of the Form 4. The page appears to be a placeholder or a very brief notice from Investing.com.
Sana Biotechnology, Inc. (SANA) Stock Price, News, Quote & History
This page provides comprehensive financial information for Sana Biotechnology, Inc. (SANA), including its current stock price, real-time quotes, and key market data. It also offers access to news, charts, historical data, and financial highlights such as market capitalization, valuation measures, profitability, and balance sheet details. The content also features related stocks that people are watching.
H.C. Wainwright Remains a Buy on Sana Biotechnology (SANA)
H.C. Wainwright analyst Emily Bodnar maintained a Buy rating on Sana Biotechnology (SANA) with a $7.00 price target. This recommendation is supported by a Strong Buy consensus from other analysts, with an average price target of $8.00. The company recently reported a quarterly GAAP net loss of $63.64 million, an improvement from $93.8 million in the previous year.
Sana Biotechnology, Inc. (SANA) Investor Outlook: A Biotech Player with a 171.89% Upside Potential
Sana Biotechnology, Inc. (SANA) is a biotech company focused on cell-based therapies with a significant potential upside of 171.89% according to analysts. Despite facing typical biotech challenges like deferred profitability and a negative return on equity, Sana is advancing a robust pipeline, including a Phase 1 clinical trial for type 1 diabetes. The company's strategic collaborations and positive free cash flow offer financial flexibility as it pursues its growth-oriented strategy.
Sana Biotechnology at citigroup’s biopharma back to school summit 2026: diabetes push
Sana Biotechnology (SANA) presented its strategy at Citigroup’s Biopharma Back to School Summit 2026, focusing on its SC451 type 1 diabetes program, which is nearing an IND filing, and its SG293 in vivo CAR T program, delayed in China. The company reported $160 million in cash, sufficient for about a year of operations, and addressed manufacturing challenges and the significant unmet need in type 1 diabetes, highlighting the potential for a functional cure. Despite a stock decline and overvaluation concerns, analysts see substantial upside potential for SANA.
Sana Biotechnology to Present at September 2026 Investor Conferences
Sana Biotechnology, Inc. announced its participation in four investor conferences in September 2026. The company will present business overviews and updates at the Wells Fargo Healthcare Conference, Citi's Biopharma Back-to-School Conference, the Morgan Stanley 24th Annual Global Healthcare Conference, and the HC Wainwright 28th Annual Global Investment Conference. Webcasts of these presentations will be available on Sana's Investor Relations page.
Sana Biotechnology to Present at September 2026 Investor Conferences
Sana Biotechnology, Inc. (NASDAQ: SANA) announced that it will present at four investor conferences in September 2026. The company will provide a business overview and update at the Wells Fargo Healthcare Conference, Citi’s Biopharma Back-to-School Conference, the Morgan Stanley Global Healthcare Conference, and the HC Wainwright Global Investment Conference. Webcasts of these presentations will be available on Sana's investor relations website.
Is Sana Biotechnology (SANA) Turning Cost Discipline Into a More Durable Investment Narrative?
Sana Biotechnology (SANA) reported a narrower net loss and reduced loss per share for Q2 2026, indicating improved cost control and financial efficiency. While these results strengthen the investment case by easing near-term cash burn worries, the company still faces challenges including a short cash runway and skepticism regarding its share price valuation. Investors are encouraged to consider multiple perspectives and risks, including the need for clinical progress in its cell and gene engineering programs.
Is Sana Biotechnology (SANA) Turning Cost Discipline Into a More Durable Investment Narrative?
Sana Biotechnology (SANA) reported a narrower net loss and reduced loss per share for Q2 2026, indicating improved cost discipline. While this strengthens the investment case by easing concerns about cash burn, the fundamental drivers remain clinical progress in its core programs. Investor opinions on the company's valuation vary widely, highlighting a need for careful consideration given the short cash runway and ongoing losses.
Will Sana Biotechnology (NASDAQ:SANA) Spend Its Cash Wisely?
This article examines Sana Biotechnology's financial health, specifically its cash reserves and burn rate, to assess its ability to fund operations. It highlights that the company has sufficient cash for over two years at its current burn rate but warns that investors should closely monitor its future cash usage and potential capital raises. The analysis suggests that while the current cash position is strong, the burn rate is high, necessitating careful management.
Sana Biotechnology, Inc. (NASDAQ:SANA) Given Average Rating of "Moderate Buy" by Analysts
Sana Biotechnology, Inc. (NASDAQ:SANA) has received an average "Moderate Buy" rating from nine analysts, with seven buy ratings, one hold, and one sell. The average 12-month price target for the stock is $9.33, significantly higher than its recent price of $3.74. Institutional investors hold a substantial 88.23% of Sana's shares, and the company recently reported a quarterly loss of $0.13 per share, beating analyst estimates.
Is Sana Biotechnology (SANA) Turning Cost Discipline Into a More Durable Investment Narrative?
Sana Biotechnology reported a narrower net loss and reduced loss per share for Q2 2026 and the first half of the year, signaling improved cost controls and financial efficiency. While this strengthens the investment case by easing concerns about cash burn, the fundamental drivers remain clinical progress and partnerships. Investors should still consider the short cash runway and "going concern" doubts.
Is Sana Biotechnology (SANA) Turning Cost Discipline Into a More Durable Investment Narrative?
Sana Biotechnology reported a narrower net loss and reduced loss per share for Q2 2026, suggesting improved cost management. While this strengthens its investment narrative by easing concerns about cash burn, investors should also consider the short cash runway and "going concern" doubts. The company's long-term success still hinges on clinical progress and its cell and gene engineering platforms.
Sana Biotechnology (NASDAQ:SANA) Stock Price Down 6.2% - Time to Sell?
Sana Biotechnology's stock price dropped 6.2% to $3.845, with trading volume significantly lower than average. Despite the dip, analyst sentiment is mixed but largely positive, with a "Moderate Buy" consensus rating and an average price target of $9.33, well above its current price. The clinical-stage biotech company also beat its quarterly earnings expectations, reporting a loss of $0.13 per share against an estimated $0.15 loss.
Can Sana Biotechnology (SANA) Justify Its Valuation On Narrower Losses?
Sana Biotechnology (SANA) recently reported narrower net losses for Q2 and H1 2026, leading to a recent positive shift in share performance despite longer-term declines. The company trades at a Price-to-Book ratio of 7x, significantly higher than the industry and peer averages, indicating an expensive valuation. While recent performance suggests some investor optimism, ongoing net losses and clinical trial uncertainties pose risks to its current premium valuation.
Can Sana Biotechnology (SANA) Justify Its Valuation On Narrower Losses?
Sana Biotechnology (SANA) recently reported narrower net losses for Q2 and H1 2026, leading to a recent positive shift in share price momentum. However, the company's Price-to-Book (P/B) ratio of 7x is significantly higher than the industry average, suggesting an overvalued status. Investors are cautioned to consider the ongoing net losses and clinical trial uncertainties despite the improved earnings.
Alphabet Inc. Makes New $9.82 Million Investment in Sana Biotechnology, Inc. $SANA
Alphabet Inc. has acquired a new stake of 2,812,500 shares in Sana Biotechnology, Inc. (NASDAQ:SANA) valued at approximately $9.82 million during the second quarter, making it their 22nd largest position. Other institutional investors have also adjusted their holdings in Sana Biotechnology. The company currently holds a "Moderate Buy" rating with a consensus price target of $9.33 from analysts.
ARCH venture funds disclose 15%+ Sana Biotechnology (SANA) ownership in updated filing
ARCH venture funds and related entities, along with several individual managers, have reported an updated collective beneficial ownership of 15.3% in Sana Biotechnology (SANA) common stock as of June 30, 2026. This amounts to 45,860,681 shares based on 299,360,637 shares outstanding. Robert Nelsen, a manager, holds an even higher stake of 15.4% when accounting for his vested options, RSUs, and family trust holdings.
Sana Biotechnology | SCHEDULE 13G/A: Others
This article is a Schedule 13G/A filing for Sana Biotechnology. It indicates an amendment to a previous filing, typically related to significant ownership of the company's stock by an institutional investor or beneficial owner. This is a standard regulatory disclosure.
Sana Biotechnology (NASDAQ:SANA) Shares Down 5.3% - Should You Sell?
Sana Biotechnology (NASDAQ:SANA) shares dropped 5.3% to $3.4750 on Friday, with trading volume significantly below average. Despite the dip, analyst sentiment is mixed but leans positive, with an average target price of $9.50, although one analyst recently downgraded the stock to "Sell." The company reported a narrower-than-expected quarterly loss of $0.13 per share and continues its focus on developing engineered-cell therapies for cancer and genetic diseases.
Sana Biotechnology, Inc. Stock 12‑Month Price Target Cut to $9.38, Implies 155% Upside
Sana Biotechnology, Inc.'s average 12-month price target has been reduced slightly from $9.5 to $9.38 by 8 analysts, with individual forecasts ranging from $6 to $16 per share. Despite the cut, the new target still suggests a significant 155% potential upside based on the Aug. 13 closing price. The consensus rating from 10 covering analysts remains a "Buy," with 9 analysts recommending Buy and 1 recommending Hold.
BofA Securities Adjusts Sana Biotechnology Price Target to $6 From $7
BofA Securities has lowered its price target for Sana Biotechnology (SANA) to $6 from $7, as reported on August 14, 2026. This adjustment follows other recent news for the company, including its Q2 adjusted loss narrowing and its removal from several Russell Value Benchmarks in late June. The article also provides a company profile, financial data, analyst consensus, and a list of recent news related to Sana Biotechnology.
HC Wainwright Has Pessimistic Outlook of SANA Q3 Earnings
HC Wainwright has lowered its Q3 2026 earnings forecast for Sana Biotechnology (NASDAQ:SANA) to a loss of $0.14 per share, anticipating continued losses through future fiscal years. Despite this, Sana's last quarterly loss of $0.13 per share exceeded analyst expectations. The stock currently holds a "Moderate Buy" consensus rating from analysts, with institutional investors owning a significant portion of its shares.
Sana Biotechnology (SANA) Is Up 13.5% After Narrower Losses And Mayo Clinic Equity Deal - What's Changed
Sana Biotechnology (SANA) saw its stock rise by 13.5% after reporting narrower losses in Q2 2026 and announcing a significant collaboration with the Mayo Clinic, which includes a $25 million equity investment. The company also made progress in its clinical trial programs and released encouraging data for its UP421 cell therapy. While these developments provide positive catalysts, the company still faces challenges such as zero revenue, ongoing losses, and a rich price-to-book multiple.
Sana Biotechnology (SANA) Is Up 13.5% After Narrower Losses And Mayo Clinic Equity Deal - What's Changed
Sana Biotechnology (SANA) reported narrower losses in Q2 2026 and announced a US$25 million equity deal with the Mayo Clinic, contributing to a 13.5% stock increase. The company also made progress in its clinical programs and unveiled promising data for its UP421 cell therapy. Despite these positive developments, the article highlights ongoing financial risks due to zero revenue, continuous losses, and an inflated share price compared to its estimated value.
Sana Biotechnology | 10-Q: Quarterly report
This document is a 10-Q Quarterly Report filed by Sana Biotechnology. It provides a formal financial and operational update for the quarter.
Sana Biotechnology Q2 Results: Adj. EPS beats estimate
Sana Biotechnology reported stronger-than-expected Q2 2026 results, with non-GAAP EPS of $(0.13) surpassing analyst estimates. The company secured $93.3 million in new funding, increasing its cash reserves to $160.5 million and extending its financial runway until mid-2027. This financial stability supports the advancement of its lead programs, SC451 and SG293, towards Phase 1/2 clinical trials this year, alongside a new strategic partnership and investment from Mayo Clinic.
Sana Biotechnology (NASDAQ:SANA) Issues Earnings Results
Sana Biotechnology (NASDAQ:SANA) reported a quarterly loss of $0.13 per share, surpassing the consensus estimate of a $0.15 loss. Following the announcement, SANA shares increased by 2.6% to $3.61. The company holds a "Moderate Buy" consensus rating from analysts with an average price target of $9.50, and institutional investors own 88.23% of its stock.
Earnings Flash (SANA) Sana Biotechnology, Inc. Posts Q2 Adjusted Loss $0.13 per Share, vs. FactSet Est of $-0.12
Sana Biotechnology, Inc. (SANA) reported a Q2 adjusted loss of $0.0.13 per share, which was narrower than the FactSet estimate of a $0.12 loss per share. The company focuses on developing engineered cells as medicines for therapeutic areas such as type 1 diabetes, oncology, and autoimmune diseases. Sana Biotechnology's stock, trading on Nasdaq, showed a 5-day change of +2.56% and a year-to-date change of -11.30% as of August 10, 2026.
Sana Biotechnology Reports Second Quarter 2026 Financial Results and Business Updates
Sana Biotechnology reported its Q2 2026 financial results, highlighting significant progress in its clinical programs for SC451 in type 1 diabetes and SG293 in non-Hodgkin lymphoma, with both expected to start clinical trials this year. The company also announced a follow-on publication in The New England Journal of Medicine for its UP421 hypoimmune-modified islet cell transplantation and a strategic collaboration with Mayo Clinic. Sana ended the quarter with $160.5 million in cash, projecting a runway into mid-2027.
Sana Biotechnology faces earnings test as CAR-T program advances
Sana Biotechnology Inc. is set to report its second-quarter results on Monday, with analysts expecting a narrower loss of 15 cents per share and no revenue. Investors will be closely watching for updates on its in vivo CAR-T platform, specifically SG293, and its stem cell-derived islet cell therapy SC451, as well as the company's cash burn and financing plans. The stock has a "strong-buy" rating from Wall Street, with an implied upside of 143% from its current trading price.
Sana Biotechnology Inc (SANA) Earnings Forecast: Future EPS & Revenue Growth Estimates
Sana Biotechnology Inc (SANA) has a target price of USD 7.00, with analysts forecasting a potential upside of 151.36%. Based on ratings from 9 analysts, the consensus for SANA stock is a "Buy." The company's EPS for the previous quarter was USD -0.21, and the next quarter is expected at USD -0.15.
Sana Biotechnology (SANA) Projected to Release Earnings on Monday
Sana Biotechnology (SANA) is expected to report its Q2 2026 earnings on Monday, August 10th, with analysts projecting a loss of $0.1469 per share. The company's shares opened at $3.08, and its market capitalization is approximately $858 million. Analyst sentiment is mixed but leans positive, with an average price target of $9.50 and institutional investors owning 88.23% of the stock.
Did Sana Biotechnology, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
Halper Sadeh LLC, an investor rights law firm, is investigating whether officers and directors of Sana Biotechnology, Inc. (NASDAQ: SANA) breached their fiduciary duties to shareholders. The firm encourages long-term Sana shareholders to contact them to discuss legal options, including seeking corporate governance reforms or the return of funds to the company. They operate on a contingent fee basis, meaning shareholders would not be responsible for out-of-pocket legal fees.